Tsuboi, Masahiro
Herbst, Roy S. http://orcid.org/0000-0003-2535-5847
John, Thomas
Kato, Terufumi
Majem, Margarita
Grohé, Christian
Wang, Jie
Goldman, Jonathan W.
Lu, Shun
de Marinis, Filippo
Shepherd, Frances A.
Lee, Ki Hyeong
Le, Nhieu Thi
Dechaphunkul, Arunee
Kowalski, Dariusz
Bonanno, Laura
Dómine, Manuel
Poole, Lynne
Bolanos, Ana
Rukazenkov, Yuri
Wu, Yi-Long
Funding for this research was provided by:
AstraZeneca
Article History
Accepted: 15 January 2024
First Online: 11 March 2024
Change Date: 21 March 2024
Change Type: Update
Change Details: The chapter 1 Summary of Research has been placed in the first page of the article
Declarations
:
: Funded by AstraZeneca; ADAURA ClinicalTrials.gov number, NCT02511106. Medical writing assistance was provided by Sally Cotterill, Ph.D., CMPP, of Ashfield MedComms, an Inizio Company, and was funded by AstraZeneca in accordance with Good Publications Practice (GPP) guidelines (ExternalRef removed).
: Please see the original article for full author disclosures. In addition to these disclosures, Masahiro Tsuboi reports invited speaker/honoraria roles: Daiichi Sankyo. Thomas John reports consulting/advisory roles: Gilead Sciences, Johnson & Johnson, Seagen, Specialised Therapeutics, and Takeda. Margarita Majem reports a consulting/advisory role with Cassen Recordatti; invitation to a speaker/speakers’ bureau from Amgen, AstraZeneca, Helssin, Merck Sharp & Dohme, Roche, and Sanofi; meeting/travel support from AstraZeneca, Merck Sharp & Dohme, and Roche; and research support from Bristol Myers Squibb. Filippo de Marinis reports a consulting/advisory role: AstraZeneca. Laura Bonanno reports consulting/advisory roles with AstraZeneca, Bristol Myers Squibb/Medarex, MSD Oncology, Novartis, and Roche/Genentech and speakers’ bureau participation with Novartis/Ipsen, AstraZeneca/MedImmune, Bristol Myers Squibb/Medarex, and Novartis/Ipsen. Manuel Dómine reports consulting/advisory roles: AstraZeneca, MSD Oncology, Pfizer, Roche, and Takeda.
: The trial was conducted in accordance with the provisions of the Declaration of Helsinki, the Good Clinical Practice guidelines of the International Council for Harmonization, applicable regulatory requirements, and the bioethics and human samples policy of the sponsor. The protocol was approved by relevant institutional review boards or ethics committees. All patients provided written informed consent. This article is based on a previously conducted study and does not contain any new data from studies with human participants or animals performed by any of the authors.
: Not applicable.
: Provision of standard data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca’s data sharing policy described at ExternalRef removed.
: Not applicable.
: All authors contributed to the development of this article and approved the final document.